Tenax Therapeutics is trading 6.6% up in pre-market at $1.45, with no verified company-specific announcement explaining the move. - This compares with its October 16 close of $1.36. An October 18 report revisited the Phase 3 LEVEL trial, which failed its primary and key secondary endpoints; that result does not explain the current rise. - The Nasdaq Composite is up 1.23% and the S&P 500 up 0.63%, while XBI is down 3.65% pre-market, leaving the cause uncertain.